Universidade Federal de Sao Paulo Researchers Describe Research in Myelogenous Leukemia [Allogeneic Hematopoietic Stem Cell Transplants (Hsct) With Adapted Flamsa Can Cure Half of The Pediatric Patients With Refractory Acute Myelogenous Leukemia...].

Předmět:	ACUTE myeloid leukemia MYELOID leukemia HEMATOPOIETIC stem cells CHILD patients STEM cell transplantation HEMATOPOIETIC stem cell transplantation
Zdroj:	Stem Cell Week; 11/9/2023, p1101-1101, 1p
Abstrakt:	Keywords: Acute Myelogenous Leukemia; Bone Marrow Cells; Cancer; Health and Medicine; Hematology; Hematopoietic; Hematopoietic Stem Cells; Leukemia; Myelogenous Leukemia; Oncology; Pediatrics; Stem Cell Research EN Acute Myelogenous Leukemia Bone Marrow Cells Cancer Health and Medicine Hematology Hematopoietic Hematopoietic Stem Cells Leukemia Myelogenous Leukemia Oncology Pediatrics Stem Cell Research 1101 1101 1 11/06/23 20231109 NES 231109 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Current study results on myelogenous leukemia have been published. HSCT in patients with active AML is controversial, but the FLAMSA regimen, a sequential cytoreduction followed by allogeneic HSCT, initially developed to treat adult patients, has been used by the BFM group with very promising results.". [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu